Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00077818
Status:
COMPLETED
Last Update Posted:
2009-10-15
First Post:
2004-02-12
Brief Title:
Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome RESCUE
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Prospective Open-label Randomized Parallel-group Investigation to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome
Status:
COMPLETED
Status Verified Date:
2009-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the efficacy and safety of enoxaparin compared to unfractionated heparin UFH for patients diagnosed with Acute Coronary Syndrome ACS in the emergency department ED Efficacy is assessed by using a composite score consisting of 30-day all-cause mortality non-fatal myocardial infarction MI and recurrent angina requiring revascularization
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None